Category: Legal Framework
FDA Deficiency Letters in Generic Drug Applications: Common Findings and How to Avoid Them
Learn why FDA sends deficiency letters for generic drug applications, the top reasons including dissolution failures and unqualified impurities, and actionable steps to avoid delays and costly rejections.
Read More
Future Legal Developments: Proposed Laws and Regulatory Changes 2026
Explore the 2026 legal landscape with key updates on labor laws, tax reforms, and regulatory changes affecting businesses and individuals.
Read More
What is an ANDA: Abbreviated New Drug Application Explained for FDA Approval
Discover what an ANDA is and how the FDA approves generic drugs. Learn the difference between ANDA and NDA, bioequivalence requirements, and the role of the Hatch-Waxman Act.
Read More
Patent Term Restoration (PTE): How It Extends Drug Patent Life
Patent Term Restoration (PTE) lets drugmakers recover lost patent time due to FDA delays. Learn how the Hatch-Waxman Act works, who qualifies, why applications get denied, and how it impacts drug prices and generic competition.
Read More
Liability and Indemnification in Generic Transactions: What You Need to Know
Indemnification clauses in commercial contracts determine who pays when things go wrong. Learn how liability protection works, what to look for in the fine print, and why ignoring these clauses can cost you millions.
Read More